Novo Nordisk’s amylin obesity drug keeps performing like Zepbound - STAT

1. Novo Nordisk’s amylin obesity drug keeps performing like Zepbound  STAT
2. Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects  Reuters
3. Novo hunts for ‘maximum potential’ from obesity drug CagriSema  Financial Times
4. Novo Nordisk Obesity Shot Tied to Greater Weight Loss at Lower Doses  Bloomberg.com
5. Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine  Yahoo Finance

from Top stories - Google News https://ift.tt/O74CFav
via Whole story